Advertisement
Advertisement

MDXG

MDXG logo

MiMedx Group, Inc

3.52
USD
Sponsored
-0.02
-0.56%
May 13, 16:00 UTC -4
Closed
exchange

After-Market

3.46

-0.06
-1.56%

MDXG Earnings Reports

Positive Surprise Ratio

MDXG beat 21 of 31 last estimates.

68%

Next Report

Date of Next Report
Jul 28, 2026
Estimate for Q2 26 (Revenue/ EPS)
$64.67M
/
-$0.03
Implied change from Q1 26 (Revenue/ EPS)
+9.62%
/
-40.00%
Implied change from Q2 25 (Revenue/ EPS)
-34.42%
/
-130.00%

MiMedx Group, Inc earnings per share and revenue

On Apr 29, 2026, MDXG reported earnings of -0.05 USD per share (EPS) for Q1 26, missing the estimate of -0.02 USD, resulting in a -77.94% surprise. Revenue reached 58.99 million, compared to an expected 66.32 million, with a -11.05% difference. The market reacted with a +8.91% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of -0.03 USD, with revenue projected to reach 64.67 million USD, implying an decrease of -40.00% EPS, and increase of 9.62% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
logo
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
logo
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
logo
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
logo
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
logo
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
logo
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-
Actual
-$0.05
Surprise
-
logo
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
logo
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
logo
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
For Q1 2026, MiMedx Group, Inc reported EPS of -$0.05, missing estimates by -77.94%, and revenue of $58.99M, -11.05% below expectations.
The stock price moved up 8.91%, changed from $3.08 before the earnings release to $3.36 the day after.
The next earning report is scheduled for Jul 28, 2026.
Based on 5 analysts, MiMedx Group, Inc is expected to report EPS of -$0.03 and revenue of $64.67M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement